

# In vitro class switching staining for flow cytometry

Ewen Gallagher (✉ [e.gallagher@ucl.ac.uk](mailto:e.gallagher@ucl.ac.uk))

UCL

ThomasENZler (✉ [tenzler@ucsd.edu](mailto:tenzler@ucsd.edu))

UCSD

Atsushi Matsuzawa

UCSD

Michael Karin

UCSD

---

## Method Article

**Keywords:** cytometry

**Posted Date:** June 26th, 2006

**DOI:** <https://doi.org/10.1038/nprot.2007.36>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

This protocol was used in our Nature Immunology paper.

## Reagents

Frosted microscope slides (Fisher Scientific, Pittsburgh, PA) RPMI-1640 medium (Cellgro) ACK Lysing Buffer (Cambrex) Cell strainers, 70 µm nylon (Becton Dickinson) CD43 (Ly-48) magnetic beads and separation columns (Miltenyi) B cell complete medium: RPMI-1640 medium (Cellgro) plus 2 mM glutamine (Gibco) and 100 U/ml of penicillin G/ml and 100 µg/ml of streptomycin (Gibco), 10% fetal calf serum (heat inactivated; Sigma), and  $5 \times 10^{-5}$  M 2-mercaptoethanol (Sigma). 24-well flat bottom culture plates (Nunc) Anti-CD40 (clone 3/23; Pharmingen) Recombinant mouse IL-4 (Peprotech) Fc blocker (anti-CD16/CD32; Pharmingen) Biotinylated anti-IgG1, anti-IgG2a-2b (both Pharmingen) Streptavidin conjugate (Pharmingen) FACS buffer: PBS + 0.5% fetal calf serum + 5mM EDTA

## Procedure

Perform the following steps at 4 °C unless indicated otherwise. 1 Harvest splenocytes by grinding of spleens in RPMI-1640 medium between two frosted microscope slides. Spin cells at 1000 RPM for 5 min. Remove erythrocytes by adding one equivalent volume of ACK Lysing Buffer to the remaining pellet. Gently resuspend, swirl tube for 1 min. Fill tube with 10 ml of RPMI-1640, centrifuge at 1000 RPM for 5 min. Resuspend in 10 ml of RPMI-1640. Filter through 70 µm nylon cell strainer. Centrifuge at 1000 RPM for 5 min. Resuspend  $1 \times 10^7$  cells in 500 µl of FACS buffer. Obtain B cells by CD43 negative purification using anti-CD43 magnetic beads. 2 Dilute CD43- B cells to a concentration of  $5 \times 10^5$  cells/ml in B cell complete medium. Use 24-well plates. Incubate  $5 \times 10^5$  B cells in presence of 10 µg/ml of anti-CD40 (clone 3/23), plus 10 ng/ml of recombinant mouse IL-4 for IgG1 analysis (6). Incubate for 4 d in a humidified 37 °C, 5% CO<sub>2</sub> incubator. 3 Wash cells with FACS buffer. Preincubate cells on ice for 10 min in presence of Fc blocker (anti-CD16/CD32). We usually use 0.5 µl of Fc blocker/  $5 \times 10^5$  cells in a total volume of 100 µl. CRITICAL STEP: Good Fc blockade. 4 Stain cells with biotinylated anti-IgG1, anti-IgG2a-2b (we used the antibodies at a dilution of 1:200 in a total volume of 100 µl). Incubate on ice for 20 min. Wash 2x with FACS buffer. 5 Stain cells with streptavidin conjugate of your choosing. Wash 2x with FACS buffer. 6 Analyze by flow cytometry.

## References

1. Anzelon, A. N., Wu, H. & Rickert, R. C. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. *Nat Immunol* **4**, 287-294 (2003).
2. Sanchez, Y. et al. Humoral and cellular immunity to hepatitis B virus-derived antigens: comparative activity of Freund complete adjuvant alum, and liposomes. *Infect Immun* **30**, 728-733 (1980).
3. Engel, P. et al. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. *Immunity* **3**, 39-50 (1995).
4. Gallagher, E. D., Xu, S., Moomaw, C., Slaughter,

C. A. & Cobb, M. H. Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation. *J Biol Chem* **277**, 45785-45792 (2002). 5. Gallagher, E. D., Gutowski, S., Sternweis, P. C. & Cobb, M. H. RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity. *J Biol Chem* **279**, 1872-1877 (2004). 6. Rush, J. S., Hasbold, J. & Hodgkin, P. D. Cross-linking surface Ig delays CD40 ligand- and IL-4-induced B cell Ig class switching and reveals evidence for independent regulation of B cell proliferation and differentiation. *J Immunol* **168**, 2676-2682 (2002).

## Acknowledgements

Supported by the National Institutes of Health (ES04151 and ES06376 to M.K.), the American Cancer Society (M.K.) and the Leukemia and Lymphoma Society of America (T.E.; SCOR grant 7332-06).